CLINICAL STUDIES
Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction
Hirofumi Soejima, MD*,
Hisao Ogawa, MD*,
Hirofumi Yasue, MD*,
Koichi Kaikita, MD*,
Keiji Takazoe, MD*,
Koichi Nishiyama, MD*,
Kenji Misumi, MD*,
Shinzo Miyamoto, MD*,
Michihiro Yoshimura, MD*,
Kiyotaka Kugiyama, MD*,
Shin Nakamura, MD and
Ichiro Tsuji, PhD
* Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto, Japan
Department of Molecular and Cellular Biology, Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
Chemo-Sero Therapeutic Research Institute, Kumamoto, Japan
Manuscript received January 4, 1999;
revised manuscript received April 22, 1999,
accepted June 11, 1999.
Reprint requests and correspondence: Dr. Hisao Ogawa, Department of Cardiovascular Medicine, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto City, 860-8556 Japan
ogawah{at}gpo.kumamoto-u.ac.jp
OBJECTIVES
We investigated the effects of enalapril therapy on plasma tissue factor (TF), tissue factor pathway inhibitor (TFPI) and monocyte chemoattractant protein-1 (MCP-1) levels in patients with acute myocardial infarction.
BACKGROUND
Macrophages express TF in human coronary atherosclerotic plaques. Both TF and TFPI are major regulators of coagulation and thrombosis. Monocyte chemoattractant protein-1 is a monocyte and macrophage chemotactic and activating factor.
METHODS
In a randomized, double-blind, placebo-controlled study beginning about two weeks after myocardial infarction, 16 patients received four weeks of placebo (placebo group) and another 16 patients received four weeks of enalapril 5 mg daily therapy (enalapril group). We performed blood sampling after administration of the doses.
RESULTS
There were no significant differences in the serum angiotensin-converting enzyme (ACE) activity, plasma TF, free TFPI or MCP-1 levels before administration between the enalapril and placebo groups. In the enalapril group, ACE activity (IU/liter) (14.0 before, 5.2 on day 3, 5.8 on day 7, 6.3 on day 28), TF levels (pg/ml) (223, 203, 182, 178) and MCP-1 levels (pg/ml) (919, 789, 790, 803) significantly decreased by day 28. However, the free TFPI levels (ng/ml) (28.2, 26.5, 26.8, 28.4) did not change. These four variables were unchanged during the study period in the placebo group.
CONCLUSIONS
This study demonstrated that administration of enalapril reduces the increased procoagulant activity in patients with myocardial infarction associated with inhibition of the activation and accumulation of macrophages and monocytes.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ECG | = electrocardiogram | | HDL | = high-density lipoprotein | | MCP-1 | = monocyte chemoattractant protein-1 | | TF | = tissue factor | | TFPI | = tissue factor pathway inhibitor |
|
This article has been cited by other articles:
|
|
|
|
 
S. M. Nelson and I. A. Greer
The potential role of heparin in assisted conception
Hum. Reprod. Update,
November 1, 2008;
14(6):
623 - 645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Campo, M. Valgimigli, P. Ferraresi, P. Malagutti, M. Baroni, C. Arcozzi, D. Gemmati, G. Percoco, G. Parrinello, R. Ferrari, et al.
Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction: Association With Genotype and Adverse Events
Arterioscler Thromb Vasc Biol,
December 1, 2006;
26(12):
2800 - 2806.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Steffel, T. F. Luscher, and F. C. Tanner
Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications
Circulation,
February 7, 2006;
113(5):
722 - 731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Bonvini, T. Hendiri, and E. Camenzind
Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target?
Eur. Heart J. Suppl.,
October 1, 2005;
7(suppl_I):
I27 - I36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon
Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
937 - 954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Zhou, A. S. Wolberg, and R. A. S. Roubey
Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep
Blood,
October 15, 2004;
104(8):
2353 - 2358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Omura, M. Yoshiyama, S. Kim, R. Matsumoto, Y. Nakamura, Y. Izumi, H. Ichijo, T. Sudo, K. Akioka, H. Iwao, et al.
Involvement of Apoptosis Signal-Regulating Kinase-1 on Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression
Arterioscler Thromb Vasc Biol,
February 1, 2004;
24(2):
270 - 275.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. J. Kereiakes
Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation
Circulation,
October 21, 2003;
108(90161):
III-22 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Jacoby and D. J. Rader
Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment
Arch Intern Med,
May 26, 2003;
163(10):
1155 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Schachinger and A. M. Zeiher
Atherogenesis--recent insights into basic mechanisms and their clinical impact
Nephrol. Dial. Transplant.,
December 1, 2002;
17(12):
2055 - 2064.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kluft, R. Kleemann, and M.P.M. de Maat
How best to counteract the enemies? By controlling inflammation in the coronary circulation
Eur. Heart J. Suppl.,
November 1, 2002;
4(suppl_G):
G53 - G65.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Jilma and P. Jilma-Stohlawetz
Female gender, menstrual cycle and estradiol affect plasma levels of monocyte chemotactic protein-1 (MCP-1) in humans
Cardiovasc Res,
August 1, 2002;
55(2):
416 - 416.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Stork, K. Baumann, C. von Schacky, and P. Angerer
The effect of 17{beta}-estradiol on MCP-1 serum levels in postmenopausal women
Cardiovasc Res,
February 15, 2002;
53(3):
642 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H.M Moons, M. Levi, and R. J.G Peters
Tissue factor and coronary artery disease
Cardiovasc Res,
February 1, 2002;
53(2):
313 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, D. K. Jin, S. H. Yang, S.-K. Lee, H. Y. Hwang, M. H. Kang, W. Kim, D. S. Kim, I. S. Choi, and E. K. Shin
Vascular Effects of Synthetic or Natural Progestagen Combined With Conjugated Equine Estrogen in Healthy Postmenopausal Women
Circulation,
April 17, 2001;
103(15):
1961 - 1966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Rauch, J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
Ann Intern Med,
February 6, 2001;
134(3):
224 - 238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. B Strawn, R. H Dean, and C. M Ferrario
Novel mechanisms linking angiotensin II and early atherogenesis
Journal of Renin-Angiotensin-Aldosterone System,
March 1, 2000;
1(1):
11 - 17.
[PDF]
|
|
|
|
